FSC / Press Release
Upstream Biosciences Inc. Announces Provisional Patent Filing of Thyroid Cancer Biomarkers
Vancouver, British Columbia CANADA, September 26, 2006 /FSC/ - Upstream Biosciences Inc. (UPBS - OTCBB), ("Upstream" or "the Company"), an emerging leader in the field of genetic diagnostics for cancer and the prediction of drug response, is pleased to announce that, on September 25, 2006 it filed a provisional patent application with the U.S. Patent and Trademark Office for certain thyroid cancer biomarkers that could be useful for determining whether patients have a genetic risk of developing thyroid cancer.
The American Cancer Society (www.cancer.org) estimates that in the year 2006 about 30,180 new cases of thyroid cancer will be diagnosed in the United States. The disease is much more common in women than men, and of the new cases diagnosed, about 22,590 will occur in women, and 7,590 in men. Nearly two-thirds of people are diagnosed between the ages of 20 and 55. In the United States alone, an estimated 870 women and 630 men will die of thyroid cancer during the year 2006.
Upstream's diagnostic markers could increase the likelihood of early detection by identifying which patients have a genetic risk of developing thyroid cancer.
"The early detection of thyroid cancer is another area that our technology can be applied to. We believe that identifying individuals with disease susceptibility is a way of prevention and the future of medicine," says Upstream CEO Joel Bellenson.
Upstream is developing diagnostic tests that may aid in the early detection of cancer by identifying individuals with disease susceptibility. Upstream is also developing diagnostic tests that may determine whether a drug will be useful or harmful to an individual patient based on his or her genetic profile. According to the Journal of the American Medical Association, each year 100,000 people die in the United States due to adverse reactions to prescription drugs.
For more information, please contact Samantha Haynes at 1-800-539-0289 or info@upstreambio.com.
About Upstream Biosciences Inc.
Founded in 2004, Upstream Biosciences Inc. is a company with the goal of becoming an emerging leader in the field of genetic diagnostics for cancer and the prediction of drug response. Upstream intends to discover, develop and license genetic-based diagnostics for cancer susceptibility and drug response. Upstream's proprietary data mining pipeline enables it to locate and analyze genetic variations in the regions of DNA 'upstream' of the gene, the 'gene switches,' which control the quantities and timing of expression of the genes and proteins important to disease and drug response. For further information please visit the Company's website at www.upstreambio.com
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements", as that term is defined in Section 27A of the United States Securities Act of 1933, as amended, and Section 21E of the United States Securities Exchange Act of 1934, as amended. Statements in this press release that are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among others, the expectation and/or claim, as applicable, that: (i) the Company is an emerging leader in the field of diagnostics for cancer and the prediction of drug response; (ii) the Company will receive demand for its biomarker technologies and the Company will meet that demand; (iii) the Company's genetic markers may be instrumental in the diagnosis and treatment of thyroid cancer, other diseases, disease susceptibility or susceptibility to prescription drugs; (iv) the Company will work with leading cancer researchers who will further validate the Company's discoveries in thyroid cancer (v) the Company may discover, develop and license its genetic based diagnostics for cancer susceptibility and drug response; (vi) the Company could develop diagnostics that could increase the likelihood of early detection of thyroid cancer by identifying which patients have a genetic risk of developing thyroid cancer and (vii) the Company's data mining pipeline may enable the Company to locate and analyze genetic variations in the regions of DNA which control the quantities and timing of expression of the genes and proteins important to disease and drug response.
Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others: (i) the risk that the Company does not execute its business plan; (ii) the inability of the Company to keep pace with technological advancements in the field of genetic diagnostics; (iii) the Company's inability to adequately protect its intellectual property or the Company's inadvertent infringement of third party intellectual property; (iv) the Company not being able to retain key employees; (v) competitors providing better or cheaper products and technologies; (vi) markets for the Company's products not developing as expected; (vii) the Company's inability to finance its operations or growth; (viii) inability to obtain all necessary government and regulatory approvals; and (ix) the inability to effectively market and commercialize the Company's technologies, including the establishment of viable relationships with third parties. These forward-looking statements are made as of the date of this news release and the Company assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although the Company believes that the beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance those beliefs, plans, expectations, or intentions will prove to be accurate. Investors should consider all of the information set forth herein and should also refer to the risk factors disclosed in the Company's periodic reports filed from time-to-time with the Securities and Exchange Commission and available at www.sec.gov.
Maximum News Dissemination by Filing Services Canada Inc.
Ph: (403) 717-3898 Fx: (403) 717-3896 www.usetdas.com |